NCT01181518
Unknown
Not Applicable
Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Poisoning by, Adverse Effect of and Underdosing of Tamoxifen
- Sponsor
- Inje University
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
- Last Updated
- 12 years ago
Overview
Brief Summary
The clinical outcome of tamoxifen treatment in breast cancer patients may be influenced by the activity of cytochrome P450 enzymes involving in tamoxifen biotransformation.
Detailed Description
The investigators investigated the prognostic and/or predictive value of genetic polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among Asian breast cancer patients.
Investigators
Jae-Gook Shin
Professor
Inje University
Eligibility Criteria
Inclusion Criteria
- •incident breast cancer patients who underwent surgery
Exclusion Criteria
- •previous cancer history before breast cancer diagnosis
Outcomes
Primary Outcomes
Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
Time Frame: five years
Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Not Applicable
Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRIBreast CancerNCT01297231Memorial Sloan Kettering Cancer Center
Completed
Phase 3
Tamoxifen StudyCardiovascular DiseasesCoronary DiseaseHeart DiseasesHypertensionMyocardial IschemiaNCT00000529NSABP Foundation Inc
Completed
Phase 4
Pharmacology of Adjuvant Hormonotherapy in Breast CancerHormono-depending Adjuvant Breast CancerNCT01127295Institut Claudius Regaud2,000
Terminated
Phase 2
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskBreast Atypical HyperplasiaBreast Lobular Carcinoma in SituBreast Atypical Lobular HyperplasiaBreast CarcinomaNCT04570956Mayo Clinic65
Unknown
Not Applicable
Decision Aids for Tamoxifen Treatment in Breast Cancer PatientsBreast CancerNCT02488603National Cancer Center, Korea360